Summary:
Double blind placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and second controlled medication.
Qualified Participants Must:
• Be 18-75 years of age
•
Be diagnosed with asthma for at least 1 year
•
Be on inhaled asthma medication
•
Have been on a second controller medication for at least 6 months
Qualified Participants May Receive:
Study related medical care, investigational medication, and compensation for time and travel.